scholarly journals Low prevalence of transmitted HIV-1 drug resistance detected by a dried blood spot (DBS)-based next-generation sequencing (NGS) method in newly diagnosed individuals in Cameroon in the years 2015–16

2018 ◽  
Vol 73 (7) ◽  
pp. 1917-1929 ◽  
Author(s):  
Herbert A Mbunkah ◽  
Alex Marzel ◽  
Stefan Schmutz ◽  
Yik Lim Kok ◽  
Osvaldo Zagordi ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Next Generation Sequencing ◽  
Dried Blood Spot ◽  
Newly Diagnosed ◽  
Next Generation ◽  
Low Prevalence ◽  
Next Generation Sequencing Ngs ◽  
Generation Sequencing ◽  
Hiv 1 ◽  
Blood Spot

Next-generation sequencing of dried blood spot specimens: a novel approach to HIV drug-resistance surveillance

2011 ◽  
Vol 16 (6) ◽  
pp. 871-878 ◽  
Author(s):  
Hezhao Ji ◽  
Yang Li ◽  
Morag Graham ◽  
Ben Binhua Liang ◽  
Richard Pilon ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Next Generation Sequencing ◽  
Dried Blood Spot ◽  
Next Generation ◽  
Hiv Drug Resistance ◽  
Novel Approach ◽  
Generation Sequencing ◽  
Blood Spot

Routine drug resistance testing in HIV-1 proviral DNA, using an automated next- generation sequencing assay

2019 ◽  
Vol 121 ◽  
pp. 104207 ◽  
Author(s):  
Enagnon Kazali Alidjinou ◽  
Pauline Coulon ◽  
Christophe Hallaert ◽  
Olivier Robineau ◽  
Agnès Meybeck ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Next Generation Sequencing ◽  
Resistance Testing ◽  
Next Generation ◽  
Proviral Dna ◽  
Drug Resistance Testing ◽  
Generation Sequencing ◽  
Hiv 1

Archived neonatal dried blood spot samples can be used for accurate whole genome and exome-targeted next-generation sequencing

2013 ◽  
Vol 110 (1-2) ◽  
pp. 65-72 ◽  
Author(s):  
Mads Vilhelm Hollegaard ◽  
Jonas Grauholm ◽  
Ronni Nielsen ◽  
Jakob Grove ◽  
Susanne Mandrup ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Dried Blood Spot ◽  
Whole Genome ◽  
Next Generation ◽  
Targeted Next Generation Sequencing ◽  
Generation Sequencing ◽  
Blood Spot

scholarly journals Clinical significance of TP53 variants as possible secondary findings in tumor-only next-generation sequencing

2019 ◽  
Vol 65 (2) ◽  
pp. 125-132
Author(s):  
Yoshihiro Yamamoto ◽  
Masashi Kanai ◽  
Tadayuki Kou ◽  
Aiko Sugiyama ◽  
Eijiro Nakamura ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Next Generation Sequencing ◽  
Informed Consent ◽  
Family History ◽  
Next Generation ◽  
Secondary Findings ◽  
Low Prevalence ◽  
Next Generation Sequencing Ngs ◽  
Generation Sequencing ◽  
Germline Testing

Abstract In tumor-only next-generation sequencing (NGS), identified variants have the potential to be secondary findings (SFs), but they require verification through additional germline testing. In the present study, 194 patients with advanced cancer who underwent tumor-only NGS between April 2015 and March 2018 were enrolled, and the incidences of possible and true SFs were evaluated. Among them, 120 patients (61.9%) harbored at least one possible SF. TP53 was the most frequent gene in which 97 variants were found in 91 patients (49.5%). Nine patients provided informed consent to undergo additional germline testing, and a total of 14 variants (BRCA1, n = 1; BRCA2, n = 2; PTEN, n = 2; RB1, n = 1; SMAD4, n = 1; STK11, n = 1; TP53, n = 6) were analyzed. Three variants (BRCA1, n = 1; BRCA2, n = 2) were confirmed to be SFs, whereas TP53 variants were confirmed to be somatic variants. To confirm the low prevalence of SFs in TP53, we analyzed 24 patients with TP53 variants who underwent a paired tumor–normal NGS assay. As expected, all TP53 variants were confirmed to be somatic variants. A total of 30 patients were tested for germline variants in TP53, but none of them resulted in true SFs, suggesting the low prevalence of SFs in this gene. Therefore, the significance of additional germline testing for TP53 variants appears to be relatively low in daily clinical practice using a tumor-only NGS assay, unless patients have any relevant medical or family history.

scholarly journals Correction: First evaluation of the Next-Generation Sequencing platform for the detection of HIV-1 drug resistance mutations in Belgium

PLoS ONE ◽  
2019 ◽  
Vol 14 (1) ◽  
pp. e0211587
Author(s):  
Géraldine Dessilly ◽  
Léonie Goeminne ◽  
Anne-thérèse Vandenbroucke ◽  
François E. Dufrasne ◽  
Anandi Martin ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Next Generation Sequencing ◽  
Next Generation ◽  
Resistance Mutations ◽  
Sequencing Platform ◽  
Drug Resistance Mutations ◽  
Next Generation Sequencing Platform ◽  
Generation Sequencing ◽  
Hiv 1
Sign in / Sign up

Export Citation Format

Share Document